The FX-LEARN Study

The Translational Medicine Program at the NewYork-Presbyterian Center for Autism and the Developing Brain is recruiting children with Fragile-X syndrome from 32 months to 6 years of age to participate in our study called FX-LEARN. Participation comes at no cost to the family, and participants will be given a reimbursement at each visit. The purpose of this study is to find out if the drug AFQ056, made by the pharmaceutical company Novartis, is safe and has beneficial effects on language learning in children who have Fragile-X syndrome (FXS). The study also aims to find out if a structured language intervention can help children with Fragile-X syndrome communicate better.

If you would like more information or would like to participate in the research study, you can email Elizabeth Aaron at ea2781@cumc.columbia.edu or call her at 914-997-5242.